{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:39:50Z","timestamp":1791470390961,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to predict HER2 status (HER2-zero, -low, and -positive) in breast cancer using MRI perfusion heterogeneity. The SHapley Additive exPlanations (SHAP) method was employed to interpret the outputs of machine learning models, which is crucial for guiding treatment with novel antibody-drug conjugates (ADCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      The retrospective study included 912 women from three centers (Center A [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009570] as the training cohort, and Centers B [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009173] and C [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009169] as external test cohorts) who underwent MRI between April 2018 and March 2024. Voxel vectors from MRI perfusion parameters (wash-in, wash-out, wash-out ratio) were clustered into subregions using k-means clustering. Radiomics features were extracted, and an XGBoost model incorporating these features was used to build the Habitat model. SHAP was applied to evaluate feature contributions and their importance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four sub-regions of tumor perfusion patterns were identified, containing 8, 8, 8, and 10 radiomics features, respectively. The Habitat model achieved AUCs of 0.902 for HER2-zero, 0.877 for HER2-low, and 0.880 for HER2-positive in Center A. In the external test cohorts, AUCs were 0.873, 0.845, and 0.865 for Center B and 0.865, 0.844, and 0.878 for Center C, respectively. SHAP analysis revealed the radiomic features that most strongly contributed to distinguishing HER2-zero, -low, and -positive tumors across the four perfusion-derived subregions. The global SHAP results identified subregion-specific features with the highest influence on model decisions, while the local SHAP explanations clarified how individual feature patterns drove prediction outcomes for specific patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Habitat model accurately predicts HER2-zero, HER2-low, and HER2-positive expression status, while SHAP clarifies the contribution of subregion-derived radiomic features and enhances the overall interpretability and clinical transparency of the prediction framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01000-4","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T02:45:14Z","timestamp":1770000314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A SHAP-interpretable XGBoost model: MRI-based intratumoral perfusion heterogeneity predicts HER2-zero, -low, and -positive ternary expression status in breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Shuxing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cici","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"1000_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"key":"1000_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J-U, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(21)00301-6.","journal-title":"Lancet Oncol"},{"key":"1000_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","volume":"72","author":"C Marchi\u00f2","year":"2021","unstructured":"Marchi\u00f2 C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123\u201335. https:\/\/doi.org\/10.1016\/j.semcancer.2020.02.016.","journal-title":"Semin Cancer Biol"},{"key":"1000_CR4","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"1000_CR5","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389:2415\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(16)32417-5.","journal-title":"Lancet"},{"key":"1000_CR6","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.esmoop.2023.101615","volume":"8","author":"G Viale","year":"2023","unstructured":"Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, et al. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open. 2023;8:101615. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101615.","journal-title":"ESMO Open"},{"key":"1000_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1000_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang G, Ren C, Li C, Wang Y, Chen B, Wen L, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 2022;20:142. https:\/\/doi.org\/10.1186\/s12916-022-02346-9.","journal-title":"BMC Med"},{"key":"1000_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41379-022-01019-5","volume":"35","author":"H Zhang","year":"2022","unstructured":"Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, mammaprint and blueprint genomic profiles. Mod Pathol. 2022;35:1075\u201382. https:\/\/doi.org\/10.1038\/s41379-022-01019-5.","journal-title":"Mod Pathol"},{"key":"1000_CR10","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.3390\/cancers13236059","volume":"13","author":"W Jacot","year":"2021","unstructured":"Jacot W, Maran-Gonzalez A, Massol O, Sorbs C, Mollevi C, Guiu S, et al. Prognostic value of HER2-Low expression in Non-Metastatic Triple-Negative breast cancer and correlation with other biomarkers. Cancers (Basel). 2021;13:6059. https:\/\/doi.org\/10.3390\/cancers13236059.","journal-title":"Cancers (Basel)"},{"key":"1000_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1515\/jtim-2024-0022","volume":"12","author":"X Shao","year":"2024","unstructured":"Shao X, Xie N, Chen Z, Wang X, Cao W, Zheng Y, et al. Inetetamab for injection in combination with Vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial. J Translational Intern Med De Gruyter. 2024;12:466\u201377. https:\/\/doi.org\/10.1515\/jtim-2024-0022.","journal-title":"J Translational Intern Med De Gruyter"},{"key":"1000_CR12","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1158\/1078-0432.CCR-18-3190","volume":"25","author":"Z Liu","year":"2019","unstructured":"Liu Z, Li Z, Qu J, Zhang R, Zhou X, Li L, et al. Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: A multicenter study. Clin Cancer Res. 2019;25:3538\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3190.","journal-title":"Clin Cancer Res"},{"key":"1000_CR13","doi-asserted-by":"publisher","first-page":"103460","DOI":"10.1016\/j.ebiom.2021.103460","volume":"69","author":"Y Yu","year":"2021","unstructured":"Yu Y, He Z, Ouyang J, Tan Y, Chen Y, Gu Y, et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study. EBioMedicine. 2021;69:103460. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103460.","journal-title":"EBioMedicine"},{"key":"1000_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","volume":"278","author":"RJ Gillies","year":"2016","unstructured":"Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than Pictures, they are data. Radiology. 2016;278:563\u201377. https:\/\/doi.org\/10.1148\/radiol.2015151169.","journal-title":"Radiology"},{"key":"1000_CR15","doi-asserted-by":"publisher","first-page":"e222646","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, et al. Multiparametric MRI and radiomics for the prediction of HER2-Zero, -Low, and -Positive breast cancers. Radiology. 2023;308:e222646. https:\/\/doi.org\/10.1148\/radiol.222646.","journal-title":"Radiology"},{"key":"1000_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tig.2020.03.005","volume":"36","author":"CB Azodi","year":"2020","unstructured":"Azodi CB, Tang J, Shiu S-H. Opening the black box: interpretable machine learning for geneticists. Trends Genet. 2020;36:442\u201355. https:\/\/doi.org\/10.1016\/j.tig.2020.03.005.","journal-title":"Trends Genet"},{"key":"1000_CR17","doi-asserted-by":"publisher","first-page":"100179","DOI":"10.1016\/j.xinn.2021.100179","volume":"2","author":"Y Xu","year":"2021","unstructured":"Xu Y, Liu X, Cao X, Huang C, Liu E, Qian S, et al. Artificial intelligence: A powerful paradigm for scientific research. Innov (Camb). 2021;2:100179. https:\/\/doi.org\/10.1016\/j.xinn.2021.100179.","journal-title":"Innov (Camb)"},{"key":"1000_CR18","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1021\/acs.jmedchem.9b01101","volume":"63","author":"R Rodr\u00edguez-P\u00e9rez","year":"2020","unstructured":"Rodr\u00edguez-P\u00e9rez R, Bajorath J. Interpretation of compound activity predictions from complex machine learning models using local approximations and Shapley values. J Med Chem. 2020;63:8761\u201377. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01101.","journal-title":"J Med Chem"},{"key":"1000_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1148\/radiol.2018172462","volume":"288","author":"J Wu","year":"2018","unstructured":"Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, et al. Intratumoral Spatial heterogeneity at perfusion MR imaging predicts Recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy. Radiology. 2018;288:26\u201335. https:\/\/doi.org\/10.1148\/radiol.2018172462.","journal-title":"Radiology"},{"key":"1000_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1148\/radiol.13122697","volume":"269","author":"RA Gatenby","year":"2013","unstructured":"Gatenby RA, Grove O, Gillies RJ. Quantitative imaging in cancer evolution and ecology. Radiology. 2013;269:8\u201315. https:\/\/doi.org\/10.1148\/radiol.13122697.","journal-title":"Radiology"},{"key":"1000_CR21","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3390\/cancers14071837","volume":"14","author":"AS Kazerouni","year":"2022","unstructured":"Kazerouni AS, Hormuth DA, Davis T, Bloom MJ, Mounho S, Rahman G, et al. Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2\u2009+\u2009Breast cancer. Cancers (Basel). 2022;14:1837. https:\/\/doi.org\/10.3390\/cancers14071837.","journal-title":"Cancers (Basel)"},{"key":"1000_CR22","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.3390\/cancers14081858","volume":"14","author":"H-H Cho","year":"2022","unstructured":"Cho H-H, Kim H, Nam SY, Lee JE, Han B-K, Ko EY, et al. Measurement of perfusion heterogeneity within tumor habitats on magnetic resonance imaging and its association with prognosis in breast cancer patients. Cancers (Basel). 2022;14:1858. https:\/\/doi.org\/10.3390\/cancers14081858.","journal-title":"Cancers (Basel)"},{"key":"1000_CR23","doi-asserted-by":"publisher","first-page":"e222830","DOI":"10.1148\/radiol.222830","volume":"308","author":"Z Shi","year":"2023","unstructured":"Shi Z, Huang X, Cheng Z, Xu Z, Lin H, Liu C, et al. MRI-based quantification of intratumoral heterogeneity for predicting treatment response to neoadjuvant chemotherapy in breast cancer. Radiology. 2023;308:e222830. https:\/\/doi.org\/10.1148\/radiol.222830.","journal-title":"Radiology"},{"key":"1000_CR24","doi-asserted-by":"publisher","first-page":"e2330603","DOI":"10.2214\/AJR.23.30603","volume":"222","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhang X, Qiu Y, Li B, Yang Z, Huang J, et al. Development and validation of MRI radiomics models to differentiate HER2-Zero, -Low, and -Positive breast cancer. AJR Am J Roentgenol. 2024;222:e2330603. https:\/\/doi.org\/10.2214\/AJR.23.30603.","journal-title":"AJR Am J Roentgenol"},{"key":"1000_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00330-023-09990-6","volume":"34","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xie X, Tang W, Chen S, Wang M, Fan Y, et al. Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer. Eur Radiol. 2024;34:899\u2013913. https:\/\/doi.org\/10.1007\/s00330-023-09990-6.","journal-title":"Eur Radiol"},{"key":"1000_CR26","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1109\/TMI.2010.2046908","volume":"29","author":"NJ Tustison","year":"2010","unstructured":"Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29:1310\u201320. https:\/\/doi.org\/10.1109\/TMI.2010.2046908.","journal-title":"IEEE Trans Med Imaging"},{"key":"1000_CR27","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to Decode the radiographic phenotype. Cancer Res. 2017;77:e104\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0339.","journal-title":"Cancer Res"},{"key":"1000_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10641-7","author":"S Zheng","year":"2024","unstructured":"Zheng S, Yang Z, Du G, Zhang Y, Jiang C, Xu T, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. Eur Radiol. 2024. https:\/\/doi.org\/10.1007\/s00330-024-10641-7.","journal-title":"Eur Radiol"},{"key":"1000_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.seminoncol.2003.08.006","volume":"30","author":"BP Zhou","year":"2003","unstructured":"Zhou BP, Hung M-C. Dysregulation of cellular signaling by HER2\/neu in breast cancer. Semin Oncol. 2003;30:38\u201348. https:\/\/doi.org\/10.1053\/j.seminoncol.2003.08.006.","journal-title":"Semin Oncol"},{"key":"1000_CR30","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1158\/1055-9965.EPI-13-1170","volume":"23","author":"SG Elias","year":"2014","unstructured":"Elias SG, Adams A, Wisner DJ, Esserman LJ, van\u2019t Veer LJ, Mali WPTM, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1464\u201383. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-1170.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1000_CR31","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American pathologists guideline update. J Clin Oncol. 2023;41:3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864.","journal-title":"J Clin Oncol"},{"key":"1000_CR32","doi-asserted-by":"publisher","first-page":"103715","DOI":"10.1016\/j.iccn.2024.103715","volume":"83","author":"J Xu","year":"2024","unstructured":"Xu J, Chen T, Fang X, Xia L, Pan X. Prediction model of pressure injury occurrence in diabetic patients during ICU hospitalization\u2013XGBoost machine learning model can be interpreted based on SHAP. Intensive Crit Care Nurs. 2024;83:103715. https:\/\/doi.org\/10.1016\/j.iccn.2024.103715.","journal-title":"Intensive Crit Care Nurs"},{"key":"1000_CR33","doi-asserted-by":"publisher","first-page":"8899","DOI":"10.1007\/s00330-023-09891-8","volume":"33","author":"L-F Wang","year":"2023","unstructured":"Wang L-F, Wang Q, Mao F, Xu S-H, Sun L-P, Wu T-F, et al. Risk stratification of gallbladder masses by machine learning-based ultrasound radiomics models: a prospective and multi-institutional study. Eur Radiol. 2023;33:8899\u2013911. https:\/\/doi.org\/10.1007\/s00330-023-09891-8.","journal-title":"Eur Radiol"},{"key":"1000_CR34","doi-asserted-by":"publisher","first-page":"100232","DOI":"10.1016\/j.esmoop.2021.100232","volume":"6","author":"Y Fan","year":"2021","unstructured":"Fan Y, Wang Y, He L, Imani S, Wen Q. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival. ESMO Open. 2021;6:100232. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100232.","journal-title":"ESMO Open"},{"key":"1000_CR35","doi-asserted-by":"publisher","first-page":"8737","DOI":"10.1007\/s00330-022-08887-0","volume":"32","author":"Y Wang","year":"2022","unstructured":"Wang Y, Lang J, Zuo JZ, Dong Y, Hu Z, Xu X, et al. The radiomic-clinical model using the SHAP method for assessing the treatment response of whole-brain radiotherapy: a multicentric study. Eur Radiol. 2022;32:8737\u201347. https:\/\/doi.org\/10.1007\/s00330-022-08887-0.","journal-title":"Eur Radiol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01000-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01000-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01000-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:30:22Z","timestamp":1781631022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01000-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01000-4","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the hospital ethics committee (Shenzhen People\u2019s Hospital, Guangzhou Red Cross Hospital and Guangzhou Women and Children\u2019s Medical Center) and the requirement for a written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}